Matched donor immune therapy for mild to moderate COVID-19
Part of Infections, Lungs & breathing clinical trials.
This early-phase study tests immune cells from a matched family donor (made to target the COVID-19 virus) to see if they can help people with mild-to-moderate COVID-19 who are hospitalized and at higher risk for getting sicker. It aims to check safety first and also look for signs of benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You are currently hospitalized and have a confirmed COVID-19 infection
- Your COVID-19 is mild or moderate right now (not severe)
- You have a matched close family donor willing to give immune cells after at least 10 days from the donor’s symptom start
- You have at least one “high-risk” health problem (such as lung disease, heart disease, diabetes, obesity, or weakened immunity)
- You do not have serious lab, pregnancy/breastfeeding, or major health-status issues that would block eligibility
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests COVID-19 treatments in people who have recently developed symptoms and who test positive for the virus. It aims to find safer, more effective options for preventing worsening disease, especially in higher-risk groups.
This trial studies whether a new treatment using stem cells from healthy donors can help people with severe or critical COVID-19. The goal is to see if it reduces inflammation and helps you recover faster.
This trial is testing whether giving special immune cells from a family donor (called CTLs) along with regular antiviral medicine is better than regular medicine alone for people who have a stubborn adenovirus or cytomegalovirus infection after a stem cell transplant.
This Phase 1 trial tests a donated immune-cell treatment (T cells) to help immunocompromised people fight or resist COVID-19 after they recently received a bone marrow or stem cell transplant. It aims to see if the treatment is safe and if it helps the body respond better to the virus.
This study tests a new antibody medicine for people with COVID-19 who are at high risk of getting very sick. If you qualify, you would receive the study drug or a placebo (inactive substance) to see if it helps you recover without needing to go to the hospital.
This early-phase study tests immune cells given from a matched donor to treat advanced non-small-cell lung cancer. It aims to see how safe the treatment is and whether it can help control the cancer.
Hear when a new Covid19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.